Elevated IL-13 in effusions of patients with HIV and primary effusion lymphoma as compared with other Kaposi sarcoma herpesvirus-associated disorders.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
3
3
2021
Statut:
ppublish
Résumé
To assess the cytokine and viral profiles of effusions and peripheral blood among patients diagnosed with HIV and Kaposi sarcoma herpesvirus [KSHV, also known as human herpesvirus 8 (HHV-8)]-associated conditions. Retrospective comparative study evaluating clinicopathologic findings in patients with HIV and KSHV-associated conditions presenting with an effusion between 2010 and 2018. Paired peripheral blood and effusion samples collected at the time of pathological diagnosis of KSHV-associated conditions [Kaposi sarcoma, KSHV-associated multicentric Castleman disease (KSHV-MCD), primary effusion lymphoma (PEL), or KSHV-associated inflammatory cytokine syndrome (KICS)] were evaluated for disease-specific and compartment-specific (effusion vs. blood) characteristics. We assessed 12 cytokines, KSHV viral DNA (KSHV-VL), and Epstein--Barr virus (EBV) viral DNA (EBV-VL). Nine patients had PEL, five patients had KSHV-MCD, and eight patients met criteria for KICS; all but one patient had concurrent Kaposi sarcoma in addition to these conditions. PEL effusions had substantially higher levels of IL-13 (median 16.9 pg/ml; interquartile range 9.7--26.9 pg/ml) compared with KSHV-MCD (median <0.114 pg/ml; P = 0.0037) or KICS (median <0.114 pg/ml; P = 0.0003) effusions. IL-13 was also higher in PEL effusions as compared with serum (median <0.12 ng/ml; P = 0.007). KSHV-VL levels were significantly higher in PEL effusions as compared with KICS effusions (median 31 × 10 vs. 569 copies/million-cell equivalent; P = 0.0005) or KSHV-MCD effusions (median 231,884 copies/million-cell equivalent; P = 0.02). PEL effusions had a distinct profile as compared to other KSHV-associated diseases with regard to elevated IL-13 and KSHV-VL. These findings may provide insights into PEL pathogenesis and aid in diagnosis.
Identifiants
pubmed: 33273183
doi: 10.1097/QAD.0000000000002692
pii: 00002030-202101010-00006
pmc: PMC7856311
mid: NIHMS1643047
doi:
Substances chimiques
Interleukin-13
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
53-62Subventions
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Références
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas . N Engl J Med 1995; 332:1186–1191.
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma . Science 1994; 266:1865- L 1869.
Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease . Blood 1995; 86:1276–1280.
Yarchoan R, Uldrick TS. HIV-associated cancers and related diseases . N Engl J Med 2018; 378:1029–1041.
Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Marshall V, Wang V, et al. Clinical features and outcomes of patients with symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: prospective characterization of KSHV Inflammatory Cytokine Syndrome (KICS) . Clin Infect Dis 2016; 62:730–738.
Polizzotto MN, Uldrick TS, Wang V, Aleman K, Wyvill KM, Marshall V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease . Blood 2013; 122:4189–4198.
Goncalves PH, Ziegelbauer J, Uldrick TS, Yarchoan R. Kaposi sarcoma herpesvirus-associated cancers and related diseases . Curr Opin HIV AIDS 2017; 12:47–56.
Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease . Blood 2001; 97:2526–2527.
Lurain K, Polizzotto MN, Aleman K, Bhutani M, Wyvill KM, Goncalves PH, et al. Viral, immunologic, and clinical features of primary effusion lymphoma . Blood 2019; 133:1753–1761.
Uldrick TS, Wang V, O’Mahony D, Aleman K, Wyvill KM, Marshall V, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease . Clin Infect Dis 2010; 51:350–358.
Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome . Front Microbiol 2012; 3:73.
Cherian S, Umerah OM, Tufail M, Panchal RK. Chylothorax in a patient with HIV-related Kaposi's sarcoma . BMJ Case Rep 2019; 12:e227641.
Pandya K, Lal C, Tuchschmidt J, Boylen CT, Sharma OP. Bilateral chylothorax with pulmonary Kaposi's sarcoma . Chest 1988; 94:1316–1317.
Bogner JR, Gross M, Zietz C, Mandel I, Zollner N. Chylothorax as fatal complication in fulminating Kaposi's sarcoma in a patient with AIDS . Klin Wochenschr 1991; 69:134.
Hussenet C, Calin R, Boussouar S, Londner C, Caby F, Tubiana R, Pourcher V. Chylothorax as a complication of Kaposi's sarcoma in an AIDS patient . Med Mal Infect 2018; 48:66–69.
Judson MA, Postic B. Chylothorax in a patient with AIDS and Kaposi's sarcoma . South Med J 1990; 83:322–324.
Priest ER, Weiss R. Chylothorax with Kaposi's sarcoma . South Med J 1991; 84:806–807.
Pennington DW, Warnock ML, Stulbarg MS. Chylothorax and respiratory failure in Kaposi's sarcoma . West J Med 1990; 152:421–422.
Maradona JA, Carton JA, Asensi V, Rodriguez-Guardado A. AIDS-related Kaposi's sarcoma with chylothorax and pericardial involvement satisfactorily treated with liposomal doxorubicin . AIDS 2002; 16:806.
Harrison M, Tomlinson D, Stewart S. Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma . J Clin Oncol 1995; 13:914–920.
Cooley T, Henry D, Tonda M, Sun S, O’Connell M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma . Oncologist 2007; 12:114–123.
Uldrick TS, Polizzotto MN, Aleman K, Wyvill KM, Marshall V, Whitby D, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease . Blood 2014; 124:3544–3552.
Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee . J Clin Oncol 1989; 7:1201–1207.
Chin Yuan C, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR assay . J Virol Methods 2001; 91:109–117.
Meso Scale Diagnostics. Proinflammatory Panel 1 (Human) Kits. https://www.mesoscale.com/∼/media/files/product%20inserts/proinflammatory%20panel%201%20human%20insert.pdf
Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses . Nature 1993; 362:248–250.
Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells . Immunol Today 1994; 15:19–26.
Wang C, Zhu C, Wei F, Zhang L, Mo X, Feng Y, et al. Constitutive activation of interleukin-13/STAT6 contributes to Kaposi's sarcoma-associated herpesvirus-related primary effusion lymphoma cell proliferation and survival . J Virol 2015; 89:10416–10426.
Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, Mak TW. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma . Blood 2002; 99:618–626.
Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma . Blood 2001; 97:250–255.
Kapp U, Yeh W-C, Patterson B, Elia AJ, Kägi D, Ho A, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells . J Exp Med 1999; 189:1939–1946.
Sanchez-Martin D, Uldrick TS, Kwak H, Ohnuki H, Polizzotto MN, Annunziata CM, et al. Evidence for a mesothelial origin of body cavity effusion lymphomas . J Natl Cancer Inst 2017; 109:djx016.
Husain SR, Obiri NI, Gill P, Zheng T, Pastan I, Debinski W, Puri RK, et al. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein . Clin Cancer Res 1997; 3:151–156.
Husain SR, Puri RK. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft . Blood 2000; 95:3506–3513.
Aoki Y, Jaffe ES, Chang Y, Jones K, Teruya-Feldstein J, Moore PS, Tosato G. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 . Blood 1999; 93:4034–4043.
Morris VA, Punjabi AS, Wells RC, Wittkopp CJ, Vart R, Lagunoff M. The KSHV viral IL-6 homolog is sufficient to induce blood to lymphatic endothelial cell differentiation . Virology 2012; 428:112–120.
Aoki Y, Tosato G. Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas . Blood 1999; 94:4247.